BRPI0507949A - inibidores de fusão de hiv multimerizados - Google Patents

inibidores de fusão de hiv multimerizados

Info

Publication number
BRPI0507949A
BRPI0507949A BRPI0507949-7A BRPI0507949A BRPI0507949A BR PI0507949 A BRPI0507949 A BR PI0507949A BR PI0507949 A BRPI0507949 A BR PI0507949A BR PI0507949 A BRPI0507949 A BR PI0507949A
Authority
BR
Brazil
Prior art keywords
multimerized
fusion proteins
hiv
inhibitors
fusion inhibitors
Prior art date
Application number
BRPI0507949-7A
Other languages
English (en)
Inventor
Michael Etzerodt
Original Assignee
Borean Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Borean Pharma As filed Critical Borean Pharma As
Publication of BRPI0507949A publication Critical patent/BRPI0507949A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIDORES DE FUSãO DE HIV MULTIMERIZADOS. A presente invenção refere-se a proteínas de fusão multiméricas são providas exibindo atividade antiviral. As proteínas de fusão compreendem a região HR2 do ectodomínio da proteína gp41 de vírus de imunodeficiência humana que está fundida a um peptídeo de domínio de multimerização tal como domínio de trimerização derivado de tetranectina. As proteínas de fusão multimerizadas podem ser usadas como inibidores de fusão de HIV no tratamento de AIDS.
BRPI0507949-7A 2004-02-23 2005-02-23 inibidores de fusão de hiv multimerizados BRPI0507949A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54620004P 2004-02-23 2004-02-23
DKPA200400283 2004-02-23
PCT/DK2005/000121 WO2005080418A2 (en) 2004-02-23 2005-02-23 Multimerised hiv fusion inhibitors

Publications (1)

Publication Number Publication Date
BRPI0507949A true BRPI0507949A (pt) 2007-07-24

Family

ID=34888853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507949-7A BRPI0507949A (pt) 2004-02-23 2005-02-23 inibidores de fusão de hiv multimerizados

Country Status (3)

Country Link
EP (1) EP1720899A2 (pt)
BR (1) BRPI0507949A (pt)
WO (1) WO2005080418A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143276A1 (en) * 2007-10-08 2009-06-04 Anaphore, Inc. Trimeric IL-1Ra
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
WO2008098182A1 (en) * 2007-02-08 2008-08-14 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
AU2008310902A1 (en) * 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric IL-1Ra
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
CA2868735C (en) 2011-03-28 2020-02-25 University Of Utah Research Foundation D-peptide conjugates comprising a membrane localizing potency-enhancing cargo molecule for inhibiting hiv entry
BR112018013872A2 (pt) 2016-01-07 2018-12-18 Navigen Inc inibidores de peptídeo d da entrada do hiv e métodos de uso
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013165A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide

Also Published As

Publication number Publication date
WO2005080418A3 (en) 2005-09-22
WO2005080418A2 (en) 2005-09-01
EP1720899A2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
Vilas Boas et al. Antiviral peptides as promising therapeutic drugs
Ghimire et al. Novel host restriction factors implicated in HIV-1 replication
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
BRPI0507949A (pt) inibidores de fusão de hiv multimerizados
MX381183B (es) Proteínas de fusión de serpina-fc de inmunoglobulina de humano y método de purificación de las mismas.
AR064720A1 (es) Microvesiculas derivadas de levadura recombinante con actividades hemostaticas y usos de las mismas
PH12021550822A1 (en) Compositions and methods for the treatment of viral infections
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
MX372833B (es) Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina.
ATE345353T1 (de) Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
WO2008118849A3 (en) Hiv-1 protease inhibitors
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
CL2012001082A1 (es) Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral.
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
AR029810A1 (es) Metodos y composiciones para la inhibicion de los acontecimientos asociados con la fusion de membrana, incluyendo la transmision de rsv
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
AR123206A1 (es) Terapia génica
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
WO2010091373A3 (en) Trimerich hiv fusion inhibitors for treating or preventing hiv infection
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IMMUNONEWCO DK APS (DK)

Free format text: TRANSFERIDO DE: BOREAN PHARMA APS

B25A Requested transfer of rights approved

Owner name: ANAPHORE, INC. (US)

Free format text: TRANSFERIDO DE: IMMUNONEWCO DK APS

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.